Liquiritin Protects Against Cardiac Fibrosis After Myocardial Fibrosis After Myocardial Infarction by Inhibiting CCL5 Expression and the NF-κB Signaling Pathway [Letter]

被引：1

作者：

Idrus, Hasta Handayani ^{[1
,2
]}

Sunarno ^{[1
]}

机构：

[1] Natl Res & Innovat Agcy BRIN, Res Org Hlth, Ctr Biomed Res, Cibinong Sci Ctr, Bogor, West Java, Indonesia

[2] Res Org Hlth, Ctr Biomed Res, Cibinong Sci Ctr, Natl Res & Innovat Agcy BRIN, Genom Bldg,Jl Raya Bogor 490,Cibinong Bogor Km 46, Bogor, West Java, Indonesia

来源：

DRUG DESIGN DEVELOPMENT AND THERAPY | 2023年 / 17卷

关键词：

D O I：

10.2147/DDDT.S405817

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

引用

页码：331 / 332

页数：2

共 4 条

[1] Trimetazidine Reduces Cardiac Fibrosis in Rats by Inhibiting NOX2-Mediated Endothelial-to-Mesenchymal Transition [J].

Chen, Xingxing ;

Xia, Xue ;

Dong, Tiancheng ;

Lin, Zhiwei ;

Du, Leilei ;

Zhou, Hao .

DRUG DESIGN DEVELOPMENT AND THERAPY, 2022, 16 :2517-2527

[2] Liquiritin Protects Against Cardiac Fibrosis After Myocardial Infarction by Inhibiting CCL5 Expression and the NF-ΚB Signaling Pathway [J].

Han, Xue ;

Yang, Yakun ;

Zhang, Muqing ;

Li, Li ;

Xue, Yucong ;

Jia, Qingzhong ;

Wang, Xiangting ;

Guan, Shengjiang .

DRUG DESIGN DEVELOPMENT AND THERAPY, 2022, 16 :4111-4125

[3]

Idrus HH, 2019, Int J Appl Pharm, V11, P1

[4] Relaxin inhibits cardiac fibrosis and endothelial-mesenchymal transition via the Notch pathway [J].

Zhou, X. ;

Chen, X. ;

Cai, J. J. ;

Chen, L. Z. ;

Gong, Y. S. ;

Wang, L. X. ;

Gao, Z. ;

Zhang, H. Q. ;

Huang, W. J. ;

Zhou, H. .

DRUG DESIGN DEVELOPMENT AND THERAPY, 2015, 9 :4599-4611

← 1 →